Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A once-daily GLP-1 receptor agonist FDA-approved for type 2 diabetes. Shorter-acting than semaglutide, with a stronger effect on postprandial glucose. Also available in a fixed-ratio combination with insulin glargine (Soliqua).
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies with potentially superior efficacy to semaglutide for weight loss.
Activates GLP-1 receptors, stimulating glucose-dependent insulin secretion and suppressing glucagon. Its shorter duration of action produces a more pronounced effect on gastric emptying and postprandial glucose compared to longer-acting GLP-1 agonists.
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing enhanced insulin secretion, appetite suppression, and metabolic improvements beyond what single-agonist drugs achieve.
- Type 2 diabetes (adjunct to diet and exercise)
- Postprandial glucose control
- Combined with basal insulin (Soliqua)
- Weight management
- Type 2 diabetes treatment
- Metabolic health improvement
- Nausea and vomiting (common, usually transient)
- Diarrhea
- Headache
- Hypoglycemia when combined with sulfonylureas
- Pancreatitis (rare)
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis risk
- Injection site reactions
- Potential thyroid concerns
FDA-approved as Adlyxin (2016) for type 2 diabetes. Also available as Soliqua 100/33 (fixed-ratio combination with insulin glargine). Less weight loss than semaglutide but better postprandial control.
FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023).
- Lixisenatide in type 2 diabetes (GetGoal trials)
2013 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.